NRx Pharmaceuticals Inc.
(NRXPW)
undefined
undefined%
At close: undefined
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to
free cash flow ratio, price per earnings, and much more.
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
Net Income | -30.15M | -39.75M | -93.06M | -51.78M | 408.43K | 66.10K | -105.03K |
Depreciation & Amortization | 5.00K | 4.00K | 2.00K | 2.00K | 0.86 | - | - |
Stock-Based Compensation | 387.00K | 3.63M | 7.79M | 730.00K | 933.90 | - | - |
Other Working Capital | 2.51M | 2.31M | -5.71M | 3.10M | -66.68K | 84.20K | -87.00K |
Other Non-Cash Items | 2.94M | -4.33M | 54.28M | 39.61M | -1.28M | -1.55M | -115.11K |
Deferred Income Tax | - | - | -1.81M | 5.72M | 70.41K | - | - |
Change in Working Capital | 5.16M | 699.00K | -4.90M | 3.45M | 4.66K | 549.63K | -1.33K |
Operating Cash Flow | -21.66M | -39.76M | -37.70M | -2.27M | -792.73K | -473.19K | -135.81K |
Capital Expenditures | -3.00K | -10.00K | -7.00K | -2.00K | -3.55 | - | - |
Acquisitions | - | - | - | - | - | - | - |
Purchase of Investments | - | -10.00K | -7.00K | - | -993.10K | -690.00K | -69.00M |
Sales Maturities Of Investments | - | - | - | - | 41.24M | 42.39K | - |
Other Investing Acitivies | - | 10.00K | 7.00K | 26.18M | 3.55 | -647.61K | -69.00M |
Investing Cash Flow | -3.00K | -10.00K | -7.00K | -2.00K | 40.25M | -647.61K | -69.00M |
Debt Repayment | -3.09M | 9.50M | - | 620.00K | - | 690.00K | - |
Common Stock Repurchased | - | - | - | - | -40.73M | - | 70.03M |
Dividend Paid | - | - | - | - | - | - | - |
Other Financial Acitivies | 1.17M | 22.71M | 26.47M | 50.00K | 1.26M | - | - |
Financial Cash Flow | 6.20M | 32.21M | 63.46M | 3.25M | -39.46M | 682.50K | 69.59M |
Net Cash Flow | -15.46M | -7.55M | 25.75M | 982.00K | -11.07K | -438.30K | 449.37K |
Free Cash Flow | -21.66M | -39.77M | -37.71M | -2.27M | -792.73K | -473.19K | -135.81K |